title: Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8.
abstract: In this study, norcanthridin (NCTD)-encapsulated liposomes were modified with a novel murine anti-human CD19 monoclonal antibody 2E8 (2E8-NCTD-liposomes) and the targeting efficiency and specific cytotoxicity of 2E8-NCTD-liposomes to CD19(+) leukemia cells were evaluated. BALB/c mice were injected with 2E8 hybridoma cells to obtain 2E8 monoclonal antibody (mAb). NCTD-liposomes were prepared by using film dispersion method. 2E8 mAbs were linked to NCTD-liposomes using post-incorporation technology. Flow cytometry showed that the targeting efficiency of purified 2E8 mAbs on CD19(+) Nalm-6 cells was 99.93%. The purified 2E8 mAbs were conjugated with NCTD-liposomes to prepare 2E8-NCTD-liposomes whose targeting efficiency on CD19(+) Nalm-6 was also 95.82%. The average size of 2E8-NCTD-liposomes was 118.32 nm in diameter. HPLC showed that the encapsulation efficiency of NCTD was 46.51%. When the molar ratio of 2E8/Mal-PEG(2000)-DSPE reached 1:50, we obtained the liposomes with 9 2E8 molecules per liposome. The targeting efficiency of 2E8-NCTD-liposomes on CD19(+) leukemia cells was significantly higher than that on CD19-leukemia cells. Similarly, the targeting efficiency of the immunoliposomes was also higher than that of the NCTD-liposomes on CD19(+) leukemia cells. Those results were consistent with those observed by laser scanning confocal microscopy. 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay demonstrated that 2E8-NCTD-liposomes specifically killed Nalm-6 cells in a dose- and time-dependent manner. The viability of Nalm-6 cells treated by 2E8-NCTD-liposomes was significantly lower than that of Molt-3 cells and it was also significantly lower than that of Nalm-6 cells treated with the same concentration of NCTD-liposomes or free NCTD. We are led to concluded that 2E8 antigen can serve as a specific targeting molecule of B lineage hematopoietic malignancies for liposome targeting, and 2E8-NCTD-liposomes can be used as a new and effective means for the treatment of B lineage hematopoietic malignancies.
authors.affiliation: Division of Hematology-Oncology, Children's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, China. zhangjy423@gmail.com
authors.forename: Jingying
authors.initials: J
authors.lastname: Zhang
authors.forename: Yongmin
authors.initials: Y
authors.lastname: Tang
authors.forename: Baiqin
authors.initials: B
authors.lastname: Qian
authors.forename: Hongqiang
authors.initials: H
authors.lastname: Sheng
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000096:biosynthesis*; D018941:Antigens, CD19 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D002214:Capsules; D045744:Cell Line, Tumor; D019070:Cell Lineage; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D015448:Leukemia, B-Cell / Q000473:pathology*; D008081:Liposomes / Q000008:administration & dosage* / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C
chemical_list: D000911:Antibodies, Monoclonal; D018941:Antigens, CD19; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002214:Capsules; D004337:Drug Carriers; D008081:Liposomes; C069741:norcantharidin
references.citation: J Control Release. 2008 Feb 18;126(1):50-8
references.pmid: 18068849
references.citation: Blood. 1988 Jan;71(1):13-29
references.pmid: 3257143
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10640-5
references.pmid: 16030145
references.citation: Anticancer Agents Med Chem. 2009 May;9(4):392-6
references.pmid: 19442040
references.citation: Biochim Biophys Acta. 2001 Aug 6;1513(2):207-16
references.pmid: 11470092
references.citation: Int J Cancer. 2009 May 1;124(9):2186-99
references.pmid: 19123473
references.citation: Cancer Res. 2002 Dec 15;62(24):7190-4
references.pmid: 12499256
references.citation: J Mol Biol. 2007 Aug 24;371(4):934-47
references.pmid: 17602702
references.citation: Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205
references.pmid: 15717745
references.citation: Clin Cancer Res. 2004 Feb 1;10(3):1100-11
references.pmid: 14871990
references.citation: J Drug Target. 2003 Feb;11(2):87-92
references.pmid: 12881194
references.citation: Biochim Biophys Acta. 2005 Jun 1;1711(1):25-32
references.pmid: 15904660
references.citation: Curr Drug Deliv. 2005 Oct;2(4):369-81
references.pmid: 16305440
references.citation: Br J Pharmacol. 2000 Feb;129(4):687-94
references.pmid: 10683193
references.citation: Biochem J. 1995 Oct 1;311 ( Pt 1):17-29
references.pmid: 7575450
references.citation: Zhonghua Er Ke Za Zhi. 2008 Jul;46(7):493-7
references.pmid: 19099803
references.citation: Nat Rev Cancer. 2002 Oct;2(10):750-63
references.pmid: 12360278
references.citation: Expert Opin Pharmacother. 2002 Dec;3(12):1739-51
references.pmid: 12472371
references.citation: Int J Oncol. 1998 May;12(5):1035-40
references.pmid: 9538125
references.citation: Nucl Med Commun. 2005 May;26(5):427-32
references.pmid: 15838425
references.citation: Clin Cancer Res. 2004 Apr 1;10(7):2530-7
references.pmid: 15073133
references.citation: Blood. 2004 Sep 1;104(5):1442-9
references.pmid: 15155467
references.citation: Biochim Biophys Acta. 1995 Mar 8;1234(1):74-80
references.pmid: 7880861
references.citation: Bioorg Chem. 2003 Feb;31(1):68-79
references.pmid: 12697169
references.citation: J Control Release. 2007 Jul 31;120(3):169-77
references.pmid: 17586082
references.citation: J Control Release. 2006 Feb 21;110(3):505-13
references.pmid: 16356575
references.citation: Clin Cancer Res. 2005 May 1;11(9):3567-73
references.pmid: 15867261
references.citation: J Huazhong Univ Sci Technolog Med Sci. 2009 Jun;29(3):273-80
references.pmid: 19513605